| Meghan Elizabeth Rogers, MS OTR/L | |
|
1222 Portland Rd Ste 10, Arundel, ME 04046-8104 | |
| (207) 337-1058 | |
| Not Available |
| Full Name | Meghan Elizabeth Rogers |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Pediatrics |
| Location | 1222 Portland Rd Ste 10, Arundel, Maine |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801670484 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XP0200X | Occupational Therapist - Pediatrics | OT4495 (Maine) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Meghan Elizabeth Rogers, MS OTR/L 240 Harvard St Apt 511, Portland, ME 04103-3537 Ph: (978) 518-2788 | Meghan Elizabeth Rogers, MS OTR/L 1222 Portland Rd Ste 10, Arundel, ME 04046-8104 Ph: (207) 337-1058 |
News Archive
Although the nation has invested billions of dollars preparing to respond to emergencies, current plans leave millions of Americans at risk because they do not account for critical problems people face when they actually try to protect themselves.
CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.
A trans-Atlantic tie up between scientists at the University of Ulster and the Tufts University School of Medicine in Boston could lead to a greater understanding of the triggers that affect cancer cells.
CombinatoRx, Incorporated, today announced that its ophthalmic collaborator, Fovea Pharmaceuticals SA, has entered into a proposed acquisition with Sanofi-Aventis. A CombinatoRx-derived combination drug candidate, Prednisporin, (FOV1101), which is a fixed dose combination of prednisolone and cyclosporine, is the most advanced product asset in the Fovea pipeline, with Phase 2b clinical studies planned for the treatment of persistent allergic conjunctivitis.
› Verified 3 days ago
Jessica Cormier, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 39 Limerick Rd, Arundel, ME 04046 Phone: 207-985-7861 Fax: 207-985-6703 | |
River Birch Occupational Therapy Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1236 Portland Rd, Arundel, ME 04046 Phone: 207-468-1293 | |
Kimberly Marion, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 39 Limerick Rd, Arundel, ME 04046 Phone: 207-985-7861 Fax: 207-985-6703 | |
Ms. Lauren Patricia Bicknell, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 39 Limerick Rd, Arundel, ME 04046 Phone: 207-735-8749 | |
Mrs. Kelly Weber, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 39 Limerick Rd, Arundel, ME 04046 Phone: 207-985-7861 | |
Ms. Kristin Winston, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 39 Limerick Rd, Arundel, ME 04046 Phone: 207-985-7861 Fax: 207-985-6703 | |
Lorie B Wyman, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1236 Portland Rd, Arundel, ME 04046 Phone: 207-468-1293 |